Castle Biosciences Inc. (CSTL) Tops Q2 EPS by 2c

Castle Biosciences Inc. (NASDAQ: CSTL) reported Q2 EPS of ($0.35), $0.02 better than the analyst estimate of ($0.37). Revenue for the quarter came in at $22.8 million versus the consensus estimate of $18.93 million.

GUIDANCE:

Castle Biosciences Inc. sees FY2021 revenue of $89-93 million, versus the consensus of $83.6 million.

For earnings history and earnings-related data on Castle Biosciences Inc. (CSTL) click here.

You May Also Be Interested In

• Blue Owl leads $2.4 billion debt deal for Iren data center
• Jiayin Group (JFIN) Reports Q2 Loss of RMB3.56
• Titan Machinery (TITN) Misses Q2 EPS by 5c ; Offers Guidance